Select Page

The prevalence of diffuse large B-cell lymphoma (DLBCL) is increasing across the world and the global market is predicted to reach a size of USD 4.3 billion by 2022* due in part to the increased technological advances in the treatment of DLBCL.

 

Study overview

Wondering how to make the most of the fast growth the DLBCL therapeutics industry is experiencing? This study captures real-world data from an awareness, trial, and usage survey (ATU) along with patient chart information to provide a holistic analysis of the development of this evolving market.  

This tracker collects information from over 100 US and 250 European hematologist/oncologists, each of whom provide data on their medical practice as well as current and historical information from 4 to 6 randomly selected later-line patient charts. 

The insights detailed in the study report allow marketing, market insights, and market research teams to gain an in-depth understanding of the DLBCL treatment market.

 

Extract from the DLBCL Study Overview (available on request)

This study deep dives on the following areas:

 

DLBCL Market Background

  • Brand penetration and shares by line 

  • Change in product usage 

  • Expected future prescribing 

  • Evolving brand awareness 

  • Differences in each EU5 country 

DLBCL Brand Performance

  • Brand penetration and shares by line 

  • Choice attributes by line of therapy 

  • Retreatment by regimen by line of therapy 

  • Share evolution and the impact of new product launches 

  • Differences in each EU5 country 

DLBCL Patient Insights

  • DLBCL patient profile by regimen (e.g., chemotherapy, CAR T-cells, and other branded agents)  

  • DLBCL patient profile by line 

  • Line by line break-out of SCT-eligible vs. ineligible patients 

  • Relapse times by regimen 

  • Diagnosis and referral process 

  • Detailed treatment pattern 

  • Planned treatment durations 

  • Patient request/role in decision process 

Did you know?

  • More than 17 phase III and 95 phase II industry-sponsored interventional studies are now in progress for treatments targeted to specific DLBCL sub-types. 
  • Although more than 50% were eligible, less than 20% of EU5 and US patients received a stem cell transplant in first-line. 

  • 80% of US but less than 40% of EU5 hem/oncs had access to CAR T-cell therapies.

Request the study overview or arrange to speak to the study director for more information about this study via the form below.

Request DLBCL Study Overview